, Volume 57, Issue 4, pp 463–467 | Cite as

α-Fetoprotein and β-Human Chorionic Gonadotropin

Their Clinical Significance as Tumour Markers
  • John J. GregoryJr
  • Jonathan L. Finlay
Leading Article


Tumour markers can aid in areas such as diagnosis, surveillance of recurrence, staging and prognosis. This article focuses on 2 tumour markers, α-fetoprotein (AFP) and β-human chorionic gonadotropin (HCG). These tumour markers have been examined for their utility as prognostic indicators in 2 different manners. First, the marker level at diagnosis has been studied to determine if it is prognostic of outcome presumably because of its relation to tumour bulk or to the biological nature of the tumour. A more recent trend has been to investigate tumour marker decline. The finding of a delayed rate of decline suggests a poorer response of the malignancy to chemotherapy. The major focus of the article will be on marker decline of AFP and HCG as prognostic tools in peripheral and central nervous system (CNS) germ cell tumours (GCTs) and hepatic tumours (hepatoblastoma and hepatocellular carcinoma).

The articles reviewed here suggest that HCG and AFP can correlate with survival if examined in specific ways, and could potentially be used to tailor treatment for individual patients. One group of authors presents data on patients with GCTs suggesting that satisfactory marker regression is an independent prognostic factor for survival. In a study of hepatoblastoma, data demonstrate that both the magnitude and rate of decline are associated with survival. Marker decline studies in hepatocellular carcinoma do not exist and marker levels at diagnosis do not appear to have a role in potential therapeutic changes. However, data on fucosylated subtype of AFP, Lens culinaris agglutinin A reactive AFP, has shown prognostic significance in hepatocellular carcinoma. The data for CNS GCTs are limited and studies examining serial cerebrospinal fluid HCG/AFP are ongoing.

In some diseases, issues relating to timing of marker sampling when examining marker decline need to be studied in greater detail. Hopefully, marker decline studies can be duplicated in the other diseases, to document a potential role in determining outcome. Further studies are needed to test the ability to alter therapy in attempts to improve survival while decreasing toxicity to patients.


Adis International Limited Germinoma Hepatoblastoma Marker Decline Lens Culinaris Agglutinin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Toner GC, Geller NL, Tan C, et al. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990; 50(18): 5904–10PubMedGoogle Scholar
  2. 2.
    Murphy BA, Motzer RJ, Mazumdar M, et al. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 1994; 73(10): 2520–6PubMedCrossRefGoogle Scholar
  3. 3.
    Stevens MJ, Norman AR, Dearnaley DP, et al. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 1995; 13(1): 87–92PubMedGoogle Scholar
  4. 4.
    Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children’s Cancer Group. J Clin Oncol 1997; 15(3): 1190–7PubMedGoogle Scholar
  5. 5.
    Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients. Cancer 1989; 64(8): 1700–7PubMedCrossRefGoogle Scholar
  6. 6.
    Stuart KE, Anand AT, Jenkins RL. Hepatocellular carcinoma in the United States: prognostic features, treatment outcome, and survival. Cancer 1996; 77(11): 2217–22PubMedCrossRefGoogle Scholar
  7. 7.
    Yamashita F, Masatoshi T, Satomura S, et al. Prognostic significance of Lens culinaris agglutinin a reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996; 111: 996–1001PubMedCrossRefGoogle Scholar
  8. 8.
    Balmaceda C, Heller G, Rosenblum M, et al. Chemotherapy without irradiation — a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. J Clin Oncol 1996; 14(11): 2908–15Google Scholar
  9. 9.
    Shibamoto Y, Takahashi M, Sasai K. Prognosis of intracranial germinoma with syncytiotrophoblastic giant cells treated by radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37(3): 505–10PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • John J. GregoryJr
    • 1
  • Jonathan L. Finlay
    • 2
  1. 1.Department of PaediatricsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Division of Paediatric OncologyNew York UniversityNew YorkUSA

Personalised recommendations